Markov chain modelling of bioassay toxicity procedures

Area of Science:

• Biostatistics
• Pharmacology
• Clinical Trial Design

Background:

• Bioassay procedures and early-phase clinical trials often involve sequential decision-making.
• Modeling these processes as Markov chains with absorbing states provides a robust mathematical framework.
• Existing methods may lack a unified approach for comparing trial designs based on various cost metrics.

Purpose of the Study:

• To develop a general framework for analyzing bioassay and toxicity testing procedures using Markov chains.
• To enable calculation of key trial metrics, including absorption probabilities and average costs.
• To facilitate a priori comparison of competing clinical trial designs.

Main Methods:

• Modeling bioassay and phase I clinical trials as first-order Markov chains with absorbing states.
• Calculating final absorption probabilities under various dose-response curve assumptions.
• Quantifying average costs: time to completion, subjects treated, toxicity events, and medication administered.

Main Results:

• A general framework for analyzing bioassay and toxicity trials is established.
• Formulas are provided for calculating absorption probabilities and average costs.
• The framework allows for quantitative, a priori comparison of different trial designs.

Conclusions:

• The Markov chain framework offers a powerful tool for optimizing bioassay and early-phase clinical trial design.
• This approach enables informed decisions by comparing trial designs based on predicted outcomes and costs.
• The methodology supports efficient resource allocation and risk assessment in drug development.